Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Amyotrophic lateral sclerosis (ALS) is a fatal neurological disorder characterised by motor neuron degeneration in the primary motor cortex, brainstem and spinal cord. In two studies, >20 genes were associated with ALS and a number of patients carried potentially pathogenic variants in multiple ALS genes.1 ,2 We investigated the burden of influence of variants on ALS phenotype, and genetic profile of familial ALS (FALS) and sporadic ALS (SALS) in Chinese patients.
From 2009 to 2014, 254 Chinese patients diagnosed as having probable or definite ALS according to El Escorial criteria,3 at our clinic centre, were enrolled for genetic study. FALS was defined as patients having a first-degree relative with ALS. Multiple neurodegenerative genes including 24 known ALS genes (SOD1, ALS2, SETX, FUS, VAPB, ANG, TARDBP, FIG4, OPTN, VCP, UBQLN2, SIGMAR1, CHMP2B, PFN1, C9ORF72, ATXN2, AR, DCTN1, NEFH, PRPH, DAO, TFG, TAF15 and GRN) were incorporated into one screening panel, for sequence analysis. Detailed methods for targeting next-generation sequencing can be seen in online supplementary materials. In short, genomic DNA was extracted from peripheral blood leucocytes, and selective Ion Sphere Particles (ISPs) with qualified DNA were sequenced on Ion 318 Chips (8 samples/chip) by Ion Personal Genome Machine (PGM) Sequencer. At least 300 000 reads with a quality score of were obtained per sample, with a coverage of ∼96.5% for targeted regions …
Contributors QL, L-yC and XZ contributed to the conception and design of the study. QL, FL, BC, CXL, XNG, RRW, MSL and XGL contributed to the acquisition and analysis of data. QL, FL, XZ and L-yC contributed to the drafting of the manuscript and figures.
Funding This study was supported by the Beijing Municipal Science and Technology Commission (grant number Z151100003915078) and the National Natural Science Foundation of China (NSFC) (grant number 81230015).
Competing interests None declared.
Patient consent Obtained.
Ethics approval The study was approved by the Institutional Ethical Review Board.
Provenance and peer review Not commissioned; externally peer reviewed.